US 11,851,502 B2
Production of T cell retargeting hetero-dimeric immunoglobulins
Stanislas Blein, La Chaux-de-Fonds (CH); Romain Ollier, La Chaux-de-Fonds (CH); Darko Skegro, La Chaux-de-Fonds (CH); and Samuel Hou, La Chaux-de-Fonds (CH)
Assigned to Ichnos Sciences SA, La Chaux-de-Fonds (CH)
Filed by Ichnos Sciences SA, La Chaux-de-Fonds (CH)
Filed on May 21, 2018, as Appl. No. 15/984,822.
Application 15/984,822 is a continuation of application No. 15/190,268, filed on Jun. 23, 2016, abandoned.
Application 15/190,268 is a continuation of application No. 14/532,923, filed on Nov. 4, 2014, granted, now 9,493,563, issued on Nov. 15, 2016.
Claims priority of application No. 13191386 (EP), filed on Nov. 4, 2013.
Prior Publication US 2018/0355064 A1, Dec. 13, 2018
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/32 (2006.01); C07K 16/46 (2006.01); C07K 16/28 (2006.01); C07K 16/42 (2006.01)
CPC C07K 16/468 (2013.01) [C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); C07K 16/2863 (2013.01); C07K 16/2878 (2013.01); C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); C07K 16/32 (2013.01); C07K 16/4291 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/526 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/622 (2013.01); C07K 2317/71 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 13 Claims
 
1. A hetero-dimeric immunoglobulin or fragment thereof, comprising:
(a) a first polypeptide that binds to Protein A comprising an epitope binding region that binds a first epitope and an immunoglobulin constant region; and
(b) a second polypeptide comprising a VH3 based epitope binding region that binds a second epitope and an immunoglobulin constant region;
wherein the VH3 based epitope binding region of the second polypeptide has a modified VH3 domain with reduced binding to Protein A compared to an unmodified VH3 domain and wherein said modified VH3 domain has a substitution at one or more of residues 57, 65, 81 or 82a according to Kabat numbering;
wherein the first and second polypeptides comprise an engineered immunoglobulin constant region with a modified CH3 domain having a protein-protein interface, wherein the protein-protein interface of the first polypeptide comprises an amino acid substitution at a position selected from the group consisting of: 3, 5, 7, 20, 22, 26, 27, 79, 81, 84, 84.2, 85.1, 86, 88 and 90 according to IMGT numbering, and wherein the protein-protein interface of the second polypeptide comprises an amino acid substitution at a position selected from the group consisting of 3, 5, 7, 20, 22, 26, 27, 79, 81, 84, 84.2, 84.4, 85.1, 86, 88 and 90 according to IMGT numbering;
wherein the epitope binding region of the first polypeptide binds a CD3 protein complex and the epitope binding region of the second polypeptide binds a cancer antigen or wherein the epitope binding region of the first polypeptide binds a cancer antigen and the epitope binding region of the second polypeptide binds the CD3 protein complex; and
wherein the epitope binding region that binds the CD3 protein complex comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 194, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 195 and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 196, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 197, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 198 and a light chain CDR3 comprising the amino acid sequences of: SEQ ID NO: 199; or
wherein the epitope binding region that binds the CD3 protein complex comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 200, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 201 and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 202, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 203, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 204 and a light chain CDR3 comprising the amino acid sequences of: SEQ ID NO: 205; or
wherein the epitope binding region that binds the CD3 protein complex comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 352, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 353 and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 354, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 355, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 356 and a light chain CDR3 comprising the amino acid sequences of SEQ ID NO: 357.